Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 4/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009113 | 0.90 | PDE4D (0.45) | QPCTPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1008443 | 0.89 | PDE4D (0.47) | PDE4DKMT2AMEN1 | |
| SCHEMBL1010197 | 0.89 | PDE4D (0.44) | QPCTPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1008748 | 0.87 | PDE4D (0.45) | QPCTPDE4DKMT2AMEN1MAPT | |
| SCHEMBL1010015 | 0.86 | CCR5 (0.45) | QPCTPDE4DCCR5 | |
| SCHEMBL1008929 | 0.85 | PDE4D (0.44) | QPCTPDE4DKMT2AMEN1 | |
| SCHEMBL1008845 | 0.84 | PDE4D (0.44) | QPCTPDE4DCETPKMT2AMEN1 | |
| SCHEMBL1009473 | 0.83 | PDE4D (0.42) | PDE4DKMT2AMEN1PDE4APDE4B | |
| SCHEMBL1010050 | 0.83 | NR3C1 (0.50) | QPCTPDE4DKMT2AMEN1MAPT | |
| SCHEMBL1011391 | 0.82 | L3MBTL1 (0.44) | PDE4DHTR2AHTR2CHTR2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268632-B1 | TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS | CHIESI FARMA SPA (IT) | 2012-08-08 | — | — | EP | claimed |
| EP-2268632-A1 | TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-01-05 | — | — | EP | claimed |
| US-7820698-B2 | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-10-26 | — | — | US | claimed |
| WO-2009127320-A1 | TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-10-22 | — | — | WO | claimed |
| EP-2110375-A1 | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-10-21 | — | — | EP | claimed |
| US-20090258905-A1 | PHOSPHODIESTERASE-4 INHIBITORS BELONGING TO THE TERTIARY AMINE CLASS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-10-15 | — | — | US | claimed |
| EP-2268632-B1 | TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS | CHIESI FARMA SPA (IT) | 2012-08-08 | — | — | EP | disclosed |
| US-7820698-B2 | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| EP-2110375-A1 | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-10-21 | — | — | EP | disclosed |
| US-20090258905-A1 | PHOSPHODIESTERASE-4 INHIBITORS BELONGING TO THE TERTIARY AMINE CLASS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258905-A1 | PHOSPHODIESTERASE-4 INHIBITORS BELONGING TO THE TERTIARY AMINE CLASS | PDE4A, PDE4B, PDE2A | QPCT 1658/4885PDE4D 9/4885CCR5 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.